We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
ASGR2 and CLEC12A as Prognostically Relevant C-Type Lectin Hubs in Glioblastoma
Summary
Scientists found two proteins called ASGR2 and CLEC12A that help aggressive brain tumors called glioblastoma shut down the body's immune system, making them harder to treat. These proteins work with immune cells that actually protect the tumor instead of fighting it, and patients with higher levels of these proteins tend to have worse outcomes. This discovery could lead to new treatments that target these proteins to help the immune system better fight brain cancer.
In glioblastoma, the strong immunosuppression of the tumor immune microenvironment fosters tumor aggressiveness and decreases the effectiveness of therapeutic interventions, including immunotherapies. An intricate network of connections among tumor cells, stroma and infiltrating immune cells sustains immunosuppression. Lectins are immunoregulatory glycan-binding receptors contributing to immunosuppression. Their targeting is proposed as an appealing strategy for anti-cancer therapy. In this work, network-based approaches were exploited to identify a lectin profile that could dissect the complexity of tumor-immunity interactions in glioblastoma. Differential co-expression analysis, employing TCGA, CGGA and GTEx databases (145, 133 and 255 samples, respectively), identified a cluster of novel C-type lectins, with ASGR2 and CLEC12A as principal hubs. Furthermore, TIMER2.0 analysis revealed that their expression was significantly associated with immunosuppressive cells. ASGR2 and CLEC12A expression was also validated by cytofluorimetric analysis on both tumor and liquid biopsies from 20 glioblastoma patients. We report that ASGR2 and CLEC12A C-type lectins are associated with tumor-infiltrating immunosuppressive myeloid subsets and discriminate patients’ poor prognosis. These results suggest that C-type lectins may contribute to the immunosuppressive network sustained by infiltrating myeloid immune cells in GB, resulting in exploitable targets for therapeutic interventions.
Sign in to start a discussion.
More Papers Like This
Glioblastoma-derived migrasomes promote migration and invasion by releasing PAK4 and LAMA4
Researchers discovered that glioblastoma brain tumor cells produce structures called migrasomes that release proteins into surrounding tissue, helping the cancer spread more aggressively. Blocking formation of these migrasomes significantly reduced tumor cell migration and invasion, identifying new potential targets for treating this deadly brain cancer.
Novel application of microparticles demonstrate myeloid uptake and induce phenotypic change within the brain tumor microenvironment 2254
Researchers demonstrated that microparticles can be taken up by myeloid cells within glioblastoma tumors and can induce phenotypic changes in tumor-associated macrophages and neutrophils, suggesting that particle-based approaches may be able to modify the immunosuppressive tumor microenvironment.
Targeting EGFR-binding protein SLC7A11 enhancing antitumor immunity of T cells via inducing MHC-I antigen presentation in nasopharyngeal carcinoma
Researchers found that a protein called SLC7A11, stabilized by the cancer-driving protein EGFR, blocks cancer cells from being recognized and destroyed by the immune system in nasopharyngeal carcinoma, and showed that the drug sorafenib can reverse this immune evasion by targeting SLC7A11.
Identification of functional immune and neuronal tumour cells in glioma
Researchers developed the Single Cell Rule Association Mining (SCRAM) computational tool to integrate RNA-inferred genomic alterations with co-occurring cell type signatures at single-cell resolution, applying it to glioma to identify functional immune and neuronal tumour cells and distinguish tumour from non-tumour cells with greater precision than existing annotation algorithms.
Knockdown of LCN2 Attenuates Brain Injury After Intracerebral Hemorrhage via Suppressing Pyroptosis
Researchers found that reducing levels of a protein called lipocalin-2 (LCN2) in the brain lessened injury severity after intracerebral hemorrhage in animal models. The protective effect was linked to suppression of pyroptosis, a form of inflammatory cell death. The study suggests that targeting LCN2 could be a potential strategy for reducing brain damage following hemorrhagic stroke.